Listen to this page using ReadSpeaker
Posts tagged IPCV

Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease

Audio Version:

Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4. The 120-participant study will be taking place at more than 30 sites. Data and knowledge gleaned from ProgStar, a natural history study for people with Stargardt disease funded by the Foundation Fighting Blindness, was used in the design of the clinical trial.
Continue Reading…